A detailed history of Dynamic Technology Lab Private LTD transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 11,352 shares of BCRX stock, worth $85,934. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,352
Previous 40,159 71.73%
Holding current value
$85,934
Previous $248,000 65.32%
% of portfolio
0.01%
Previous 0.03%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$6.41 - $8.69 $184,652 - $250,332
-28,807 Reduced 71.73%
11,352 $86,000
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $165,856 - $272,679
40,159 New
40,159 $248,000
Q3 2023

Nov 14, 2023

SELL
$6.71 - $7.92 $108,809 - $128,430
-16,216 Reduced 41.77%
22,609 $160,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $270,222 - $342,048
38,825 New
38,825 $273,000
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $72,903 - $165,211
9,240 Added 51.28%
27,257 $288,000
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $208,276 - $356,015
18,017 New
18,017 $293,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $299,333 - $413,926
-26,774 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $380,458 - $472,561
26,774 New
26,774 $385,000
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $69,574 - $112,170
-20,284 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $55,196 - $162,976
-29,051 Reduced 58.89%
20,284 $97,000
Q1 2020

May 13, 2020

BUY
$1.6 - $4.11 $78,936 - $202,766
49,335 New
49,335 $99,000
Q4 2018

Feb 13, 2019

SELL
$6.51 - $9.6 $104,394 - $153,945
-16,036 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $88,518 - $128,127
16,036 New
16,036 $122,000
Q3 2017

Nov 08, 2017

SELL
$4.1 - $5.97 $106,128 - $154,533
-25,885 Closed
0 $0
Q2 2017

Aug 17, 2017

BUY
N/A
25,885
25,885 $144,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.